These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17003918)

  • 21. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y; Hunt RH
    Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Marwali MR; Mehta JL
    Thromb Haemost; 2006 Oct; 96(4):401-6. PubMed ID: 17003914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    Bäck M; Yin L; Ingelsson E
    Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Mateos JL
    Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiovascular events: a class effect by COX-2 inhibitors].
    Araujo LF; Soeiro Ade M; Fernandes Jde L; Serrano Júnior CV
    Arq Bras Cardiol; 2005 Sep; 85(3):222-9. PubMed ID: 16200274
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
    Antoniou K; Malamas M; Drosos AA
    Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction - The coxib controversies.
    Rainsford KD
    Inflammopharmacology; 2005; 13(4):331-41. PubMed ID: 16354388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiovascular risk of cyclooxygenase selective inhibitors].
    Terán-Estrada L; Miranda-Limón JM; Galván-Villegas F
    Rev Med Inst Mex Seguro Soc; 2008; 46(3):287-99. PubMed ID: 19133206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs.
    Ravaud P; Tubach F
    Joint Bone Spine; 2005 Dec; 72(6):451-5. PubMed ID: 16330235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.